Published November 15, 2012
Intarcia Therapeutics said it raised $210 million, enabling the biotechnology company to fund late-stage clinical trials for a new diabetes treatment without forming an alliance with a major drug maker. [ read more ]
Utah Business Social
CXO of the Year 2015Jun 25, 2015Utah Business Magazine along with Stoel Rives - are proud to present the 2015 CXO of the Year Awa...
Fast 50 - NOMINATIONS OPENAug 27, 2015NOMINATIONS OPEN -- Deadline June 26, 2015
The top 50 companies will be se...